These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37691560)

  • 1. Interim decision making in seamless trial designs: An application in an adaptive dose-finding study in a rare kidney disease.
    Papachristofi O; Bornkamp B; Wright M; Friede T
    Pharm Stat; 2024; 23(1):20-30. PubMed ID: 37691560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial.
    Cerqueira FP; Jesus AMC; Cotrim MD
    Ther Innov Regul Sci; 2020 Jan; 54(1):246-258. PubMed ID: 32008232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
    Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
    Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov.
    Bothwell LE; Avorn J; Khan NF; Kesselheim AS
    BMJ Open; 2018 Feb; 8(2):e018320. PubMed ID: 29440155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R.
    Friede T; Stallard N; Parsons N
    Biom J; 2020 Sep; 62(5):1264-1283. PubMed ID: 32118317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian adaptive designs for multi-arm trials: an orthopaedic case study.
    Ryan EG; Lamb SE; Williamson E; Gates S
    Trials; 2020 Jan; 21(1):83. PubMed ID: 31937341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations.
    Schmidli H; Bretz F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):635-43. PubMed ID: 16972715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive designs in clinical trials: why use them, and how to run and report them.
    Pallmann P; Bedding AW; Choodari-Oskooei B; Dimairo M; Flight L; Hampson LV; Holmes J; Mander AP; Odondi L; Sydes MR; Villar SS; Wason JMS; Weir CJ; Wheeler GM; Yap C; Jaki T
    BMC Med; 2018 Feb; 16(1):29. PubMed ID: 29490655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient recruitment strategies for adaptive enrichment designs with time-to-event endpoints.
    Uozumi R; Yada S; Kawaguchi A
    BMC Med Res Methodol; 2019 Jul; 19(1):159. PubMed ID: 31331277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical characteristics of adaptive design in phase 2 and 3 clinical trials.
    Sato A; Shimura M; Gosho M
    J Clin Pharm Ther; 2018 Apr; 43(2):170-180. PubMed ID: 28850685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seamless phase II/III design: a useful strategy to reduce the sample size for dose optimization.
    Jiang L; Yuan Y
    J Natl Cancer Inst; 2023 Sep; 115(9):1092-1098. PubMed ID: 37243720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies.
    Li Q; Lin J; Lin Y
    Contemp Clin Trials; 2020 Nov; 98():106096. PubMed ID: 32739496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.
    Bretz F; Schmidli H; König F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):623-34. PubMed ID: 16972714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving Probabilities of Correct Interim Decision in Population Enrichment Designs.
    Götte H; Donica M; Mordenti G
    J Biopharm Stat; 2015; 25(5):1020-38. PubMed ID: 24914474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity.
    Lin R; Yuan Y
    Biostatistics; 2020 Oct; 21(4):807-824. PubMed ID: 30984972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive seamless designs with interim treatment selection: a case study in oncology.
    Carreras M; Gutjahr G; Brannath W
    Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim decision-making strategies in adaptive designs for population selection using time-to-event endpoints.
    Uozumi R; Hamada C
    J Biopharm Stat; 2017; 27(1):84-100. PubMed ID: 26881477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive designs in critical care trials: a simulation study.
    Li W; Cornelius V; Finfer S; Venkatesh B; Billot L
    BMC Med Res Methodol; 2023 Oct; 23(1):236. PubMed ID: 37853343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.